Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932937 | 0.83 | GAA (0.50) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL12064047 | 0.81 | GAA (0.56) | CES1TDP1MAPTKMT2ASRC | |
| SCHEMBL29064653 | 0.81 | CES1 (0.43) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL11284817 | 0.79 | CES1 (0.52) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL9821868 | 0.79 | GAA (0.47) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL7199995 | 0.79 | SRC (0.49) | CES1TDP1MAPK1HPGDKDM4E | |
| SCHEMBL10458191 | 0.78 | GAA (0.53) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL7198657 | 0.78 | NR4A2 (0.50) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL28979349 | 0.78 | CES1 (0.52) | CES1TDP1MAPK1MAPTCYP3A4 | |
| SCHEMBL10943699 | 0.78 | ALDH1A1 (0.50) | CES1TDP1MAPTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610663-B2 | Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160972-A1 | Compositions and methods for modulating RNA | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6358931-B1 | OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160972-A1 | Compositions and methods for modulating RNA | RNGTT, NSUN3, NSUN2 | CES1 2698/4885TDP1 351/4885MAPK1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.